These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 33114553)

  • 1. Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics.
    Gavriilaki M; Kimiskidis VK; Gavriilaki E
    Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33114553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.
    Chamberlain JL; Huda S; Whittam DH; Matiello M; Morgan BP; Jacob A
    J Neurol; 2021 May; 268(5):1643-1664. PubMed ID: 31482201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders.
    Miyamoto K; Minamino M; Kuwahara M; Tsujimoto H; Ohtani K; Wakamiya N; Katayama KI; Inoue N; Ito H
    Front Immunol; 2023; 14():1090548. PubMed ID: 36936980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders.
    Stathopoulos P; Dalakas MC
    Expert Rev Clin Immunol; 2022 Sep; 18(9):933-945. PubMed ID: 35899480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement Inhibition in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder.
    Dodig D; Genge A; Selchen D; Freedman MS
    Can J Neurol Sci; 2023 Mar; 50(2):165-173. PubMed ID: 34895385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.
    Hakobyan S; Luppe S; Evans DR; Harding K; Loveless S; Robertson NP; Morgan BP
    Mult Scler; 2017 Jun; 23(7):946-955. PubMed ID: 27613120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementopathies and precision medicine.
    Gavriilaki E; Brodsky RA
    J Clin Invest; 2020 May; 130(5):2152-2163. PubMed ID: 32310222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders.
    Thompson KK; Tsirka SE
    Handb Exp Pharmacol; 2022; 272():245-265. PubMed ID: 34595582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic Apheresis in Neurological Disorders].
    Nakatsuji Y
    Brain Nerve; 2021 May; 73(5):425-430. PubMed ID: 34006672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review.
    Shahmohammadi S; Doosti R; Shahmohammadi A; Mohammadianinejad SE; Sahraian MA; Azimi AR; Harirchian MH; Asgari N; Naser Moghadasi A
    Mult Scler Relat Disord; 2019 Jan; 27():350-363. PubMed ID: 30476871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement in neurological disorders and emerging complement-targeted therapeutics.
    Dalakas MC; Alexopoulos H; Spaeth PJ
    Nat Rev Neurol; 2020 Nov; 16(11):601-617. PubMed ID: 33005040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System.
    Carpanini SM; Torvell M; Morgan BP
    Front Immunol; 2019; 10():362. PubMed ID: 30886620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel emerging treatments for NMOSD.
    Selmaj K; Selmaj I
    Neurol Neurochir Pol; 2019; 53(5):317-326. PubMed ID: 31664710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal dysfunction in neuroinflammatory diseases: Multiple sclerosis, neuromyelitis optica, acute autonomic ganglionopathy and related conditions.
    Sakakibara R
    Auton Neurosci; 2021 May; 232():102795. PubMed ID: 33740560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-complement Agents for Autoimmune Neurological Disease.
    McCombe JA; Pittock SJ
    Neurotherapeutics; 2022 Apr; 19(3):711-728. PubMed ID: 35553024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of the application of glucocorticoids in eight pediatric neurological disorders in China].
    ; ;
    Zhonghua Er Ke Za Zhi; 2021 Oct; 59(10):847-852. PubMed ID: 34587681
    [No Abstract]   [Full Text] [Related]  

  • 18. Hematopoietic stem cell transplantation for uncommon immune-mediated neurological disorders: A literature review.
    Jaime-Pérez JC; Meléndez-Flores JD; Ramos-Dávila EM; González-Treviño M; Gómez-Almaguer D
    Cytotherapy; 2022 Jul; 24(7):676-685. PubMed ID: 35193829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmapheresis in neurological disorders: six years experience from University Clinical center Tuzla.
    Sinanović O; Zukić S; Burina A; Pirić N; Hodžić R; Atić M; Alečković-Halilović M; Mešić E
    F1000Res; 2017; 6():1234. PubMed ID: 28928949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral memory B cells in multiple sclerosis vs. double negative B cells in neuromyelitis optica spectrum disorder: disease driving B cell subsets during CNS inflammation.
    Tieck MP; Vasilenko N; Ruschil C; Kowarik MC
    Front Cell Neurosci; 2024; 18():1337339. PubMed ID: 38385147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.